Disclosed are the ERK inhibitors of formula (1.0) and the pharmaceutically acceptable salts, and solvates thereof, wherein the variable Q is a tetrahydopyridinyl ring, and all other substituents are as defined in the specification. These compounds are suitable for treating cancer selected from the group consisting of: lung cancer, pancreatic cancer, colon cancer, colorectal cancer, myeloid leukemias, thyroid cancer, myelodysplastic syndrome, bladder carcinoma, epidermal carcinoma, melanoma, breast cancer, prostate cancer, head and neck cancers, ovarian cancer, brain cancers, cancers of mesenchymal origin, sarcomas, tetracarcinomas, nuroblastomas, kidney carcinomas, hepatomas, non-Hodgkin's lymphoma, multiple myeloma, thryroid cancer and anaplastic thyroid carcinoma.
